With IgG isotype nanoparticles (control), between 83% and 91.4% of the cancer cells remained in the blood samples, with anti-EpCAM nanoparticles only 0.8 to 1.5% remained (Figure 4a,b). This evidence concerns the gene EPCAM and cancer.